EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality

Miriam Olivola, Filippo Mazzoni, Barbara Tarantino, Alessandro Guffanti, Matteo Marcatili, Monica Macellaro, Nicolaja Girone, Vassilis Martiadis, Fabiola Raffone, Tiziano Prodi, Natascia Brondino, Giovanni Martinotti und 3 weitere

Frontiers in Psychiatry · 22.01.2026 · 16

DOI: 10.3389/fpsyt.2025.1736114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 22.01.2026. Verfasst von Miriam Olivola und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, was approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamine may enhance neuroplasticity, facilitating the reconnection with emotional and cognitive processes, improving mentalization and social cognition, and promoting resilience.

Objective

This prospective multicenter observational study aimed to evaluate esketamine’s therapeutic impact on both depressive symptoms and key psychological factors—including mentalization, psychache, social cognition, suicidality, and cognitive-emotional rigidity—that could predict treatment response and enable a more personalized approach to TRD and TRBD management.

Methods

Thirty-six treatment-resistant depressive episode patients, including TRD and TRB, treated with esketamine were assessed over a six-month follow-up period using psychometric measures of depression severity, suicidality, mentalization, social cognition, psychache, and cognitive-emotional rigidity.

Results

A significant improvement in depressive symptoms was observed, as indicated by a reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) scores over time. Moreover, improvement was observed in different key psychological domains, such as mentalization, psychache, social cognition, suicidality, and cognitive-emotional rigidity. By six months, 69% of patients achieved remission, confirming a robust and sustained therapeutic response.

Conclusions

These findings highlight the importance of a personalized treatment approach in treatment- resistant depressive episode patients. Esketamine may be particularly beneficial in reducing cognitive rigidity, improving mentalization, and breaking the cognitive inflexibility that contributes to sustained negative depressive thinking patterns. Further research is needed to refine patient stratification and optimize treatment strategies for individuals with treatment-resistant depressive episode patients.

Schlagwörter

Stichwörter der Autor:innen

cognitive rigidityesketaminemajor depressive disordermentalizationpsychachetreatment-resistant depression

Autor:innen und Institutionen

  • Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
  • Department of Mental Health and Addiction Services, Azienda Socio Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Milan, Italy.
  • Department of Mental Health, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) San Gerardo dei Tintori, Monza, Italy.
  • Department of Mental Health, University of Milan, Milan, Italy.
  • Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy.
  • Department of mental health , Azienda Sanitaria Locale (ASL) Naples 1 Centre, Naples, Italy.

Zitieren

APA

Olivola, M., Mazzoni, F., Tarantino, B., Guffanti, A., Marcatili, M., Macellaro, M., Girone, N., Martiadis, V., Raffone, F., Prodi, T., Brondino, N., Martinotti, G., Clerici, M., Anniverno, R., & Dell'Osso, B. (2026). Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1736114

Vancouver

Olivola M, Mazzoni F, Tarantino B, Guffanti A, Marcatili M, Macellaro M, et al. Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality. Frontiers in Psychiatry. 2026;16. doi:10.3389/fpsyt.2025.1736114

BibTeX
@article{Olivola2026,
  author = {Olivola, Miriam and Mazzoni, Filippo and Tarantino, Barbara and Guffanti, Alessandro and Marcatili, Matteo and Macellaro, Monica and Girone, Nicolaja and Martiadis, Vassilis and Raffone, Fabiola and Prodi, Tiziano and Brondino, Natascia and Martinotti, Giovanni and Clerici, Massimo and Anniverno, Roberta and Dell'Osso, Bernardo},
  title = {Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality},
  journal = {Frontiers in Psychiatry},
  year = {2026},
  volume = {16},
  doi = {10.3389/fpsyt.2025.1736114}
}
Kostenlos starten →